MedTrace Logo

Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

NCT07058337 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-10

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of intraocular methotrexate (MTX) in preventing and managing proliferative vitreoretinopathy (PVR) in patients undergoing retinal detachment surgery

Conditions

  • Retinal Detachment

Interventions

PROCEDURE

parsplana vitrectomy

23 gauge parsplana vitrectomy

PROCEDURE

adjunctive use of Methotrexate

intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively

Sponsors & Collaborators

  • Benha University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-09
Primary Completion
2025-06-01
Completion
2025-06-09

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07058337 on ClinicalTrials.gov